- Home
- NGNE vs MCFT Comparison
NGNE vs MCFT Comparison
Compare NGNE & MCFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- MCFT
- Stock Information
- Founded
- NGNE 2003
- MCFT 1968
- Country
- NGNE United States
- MCFT United States
- Employees
- NGNE N/A
- MCFT N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- MCFT Marine Transportation
- Sector
- NGNE Health Care
- MCFT Industrials
- Exchange
- NGNE Nasdaq
- MCFT Nasdaq
- Market Cap
- NGNE 325.3M
- MCFT 315.8M
- IPO Year
- NGNE N/A
- MCFT 2015
- Fundamental
- Price
- NGNE $18.48
- MCFT $21.94
- Analyst Decision
- NGNE Strong Buy
- MCFT Hold
- Analyst Count
- NGNE 7
- MCFT 6
- Target Price
- NGNE $41.86
- MCFT $21.50
- AVG Volume (30 Days)
- NGNE 110.1K
- MCFT 161.0K
- Earning Date
- NGNE 08-11-2025
- MCFT 08-27-2025
- Dividend Yield
- NGNE N/A
- MCFT N/A
- EPS Growth
- NGNE N/A
- MCFT N/A
- EPS
- NGNE N/A
- MCFT 0.43
- Revenue
- NGNE N/A
- MCFT $284,203,000.00
- Revenue This Year
- NGNE N/A
- MCFT $15.58
- Revenue Next Year
- NGNE N/A
- MCFT $4.25
- P/E Ratio
- NGNE N/A
- MCFT $33.75
- Revenue Growth
- NGNE N/A
- MCFT N/A
- 52 Week Low
- NGNE $6.88
- MCFT $14.39
- 52 Week High
- NGNE $74.49
- MCFT $23.50
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- MCFT 60.94
- Support Level
- NGNE $19.59
- MCFT $20.83
- Resistance Level
- NGNE $20.46
- MCFT $23.50
- Average True Range (ATR)
- NGNE 1.23
- MCFT 0.82
- MACD
- NGNE -0.20
- MCFT 0.18
- Stochastic Oscillator
- NGNE 13.37
- MCFT 60.61
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About MCFT MasterCraft Boat Holdings Inc.
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.